Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?
Clicks: 317
ID: 12880
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Star Article
77.9
/100
313 views
255 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.
| Reference Key |
ramacciottidirectclinical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ramacciotti, Eduardo;Agati, Leandro B;Caffaro, Roberto Augusto;Volpiani, Giuliano G;Lopes, Renato D;Comerota, Anthony J;Fareed, Jawed; |
| Journal | clinical and applied thrombosis/hemostasis : official journal of the international academy of clinical and applied thrombosis/hemostasis |
| Year | Year not found |
| DOI |
10.1177/1076029619856433
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.